[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466941":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":23,"locations":33,"responsibleParty":52,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":11,"overallStatus":36,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CTC positive","ACTIVE_COMPARATOR",null,[13],"Device: GILUPI CellCollector®",{"label":15,"type":6,"description":11,"interventionNames":16},"CTC negative",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DEVICE","GILUPI CellCollector®","Use of GILUPI CellCollector® to detect CTC",[15,9],[24,29],{"name":25,"role":26,"phone":27,"phoneExt":11,"email":28},"Wenji Yin","CONTACT","86(21)68385569","followroad@163.com",{"name":30,"role":26,"phone":31,"phoneExt":11,"email":32},"Qi Lu","86(21)68383364","rjllb3364@163.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Renji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","Shanghai Municipality","200127","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49],{"name":50,"role":26,"phone":11,"phoneExt":11,"email":51},"Jinsong Lu, MD","lujjss@163.com",{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Wenjin Yin","Deputy Chief of Breast Surgery Department","100466941","ctcs-in-breast-cancer-after-neoadjuvant-treatment-and-surgery-a-multicenter-prospective-clinical-trial-100466941",false,"NCT05360290","CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial","The Value of Circulating Tumor Cells in Patients With Breast Cancer Who Completed Surgery After Neoadjuvant Treatment: a Multicenter, Prospective Clinical Trial","CTCNeoBC-E","Inclusion Criteria:\n\n* Female, aged ≥18 and ≤70 years;\n* Histologically confirmed invasive breast cancer (cT2-4N0-2M0 or cT1N1-3M0 before neoadjuvant treatment);\n* Completed neoadjuvant treamtment and surgery (within 4 years after surgery);\n* Administered neoadjuvant chemotherapy (regardless of chemotherapy regimen);\n* ECOG 0-1\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV);\n* Female patients who are pregnancy or lactation;\n* Uncontrollable puncture site infection or systemic infection;","FEMALE","18 Years","70 Years",{"count":68,"type":69},484,"ESTIMATED","INTERVENTIONAL",[72],"NA","The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients who completed surgery after neoadjuvant treatment.",[75,76],"Breast Cancer","Circulating Tumor Cell","2026-02-01",{"date":79,"type":80},"2026-02-03","ACTUAL",{"date":82,"type":80},"2022-09-14",{"date":84,"type":69},"2029-06",{"name":5,"class":6},1]